Evidence map›Paper›PMID 34691016›Full record

ArticleFrontiers in immunology2021

Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2.

Xunyan Ye, Laura S Angelo, Erin G Nicholson, Obinna P Iwuchukwu, Wanderson Cabral de Rezende, Anubama Rajan, Letisha O Aideyan, Trevor J McBride, Nanette Bond, Patricia Santarcangelo and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Xunyan YeDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Laura S AngeloDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Erin G NicholsonDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Obinna P IwuchukwuDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Wanderson Cabral de RezendeDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Anubama RajanDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Letisha O AideyanDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Trevor J McBrideDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Nanette BondDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Patricia SantarcangeloDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Yolanda J RayfordDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Laura Ferlic-StarkDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Sonia FragosoDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Zoha MominDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Hongbing LiuDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Khanghy TruongDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Brianna LopezDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Margaret E ConnerDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Andrew P RiceDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Jason T KimataDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Vasanthi AvadhanulaDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Pedro A PiedraDepartment of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, United States.
Baylor College of Medicine · US

Funding

Initiative for Maximizing Student Development (IMSD) ProgramR25GM056929 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 1998 to 2023
$12.4M
Texas Developmental Center for AIDS ResearchP30AI161943 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI SCHMITZ, JOY MARIE · 2021 to 2025
$8.3M
YEARS 19 - 23: BCM POST-BACCALAUREATE RESEARCH EDUCATION PROGRAMR25GM069234 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 2003 to 2024
$7.5M
NIAID NIH HHS P30 AI161943NIGMS NIH HHS R25 GM056929NIGMS NIH HHS R25 GM069234
6 · The paper itself

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, China, and then rapidly spread causing an unprecedented pandemic. A robust serological assay is needed to evaluate vaccine candidates and better understand the epidemiology of coronavirus disease (COVID-19). Methods: We used the full-length spike (S) protein of SARS-CoV-2 for the development of qualitative and quantitative IgG and IgA anti-S enzyme linked immunosorbent assays (ELISA). A total of 320 sera used for assay development were comprised of pandemic sera from SARS-CoV-2 infected adults (n=51) and pre-pandemic sera (n=269) including sera from endemic human coronavirus infected adults. Reverse cumulative curves and diagnostic test statistics were evaluated to define the optimal serum dilution and OD cutoff value for IgG anti-S and IgA anti-S ELISAs. The IgG and IgA anti-S, and three functional antibodies (ACE-2 receptor blocking antibody, lentipseudovirus-S neutralizing antibody, and SARS-CoV-2 neutralizing antibody) were measured using additional SARS-CoV-2 PCR positive sera (n=76) and surveillance sera (n=25). Lastly, the IgG and IgA anti-S levels were compared in different demographic groups. Results: The optimal serum dilution for the qualitative IgG anti-S ELISA was at 1:1024 yielding a 99.6% specificity, 92.2% sensitivity, 92.9% positive predictive value (PPV), and 99.6% negative predictive value (NPV) at a SARS-CoV-2 seroprevalence of 5%. The optimal serum dilution for the qualitative IgA anti-S ELISA was at 1:128 yielding a 98.9% specificity, 76.5% sensitivity, 78.3% PPV, and 98.8% NPV at the same seroprevalence. Significant correlations were demonstrated between the IgG and IgA (r=0.833 for concentrations, r=0.840 for titers) as well as between IgG and three functional antibodies (r=0.811-0.924 for concentrations, r=0.795-0.917 for titers). The IgG and IgA anti-S levels were significantly higher in males than females (p<0.05), and in adults with moderate/severe symptoms than in adults with mild/moderate symptoms (p<0.001). Conclusion: We developed a highly specific and sensitive IgG anti-S ELISA assay to SARS-CoV-2 using full length S protein. The IgG anti-S antibody level was strongly associated with IgA and functional antibody levels in adults with SARS-CoV-2 infection. Gender and disease severity, rather than age, play an important role in antibody levels.

Indexed as

AdultAntibodies, ViralCOVID-19COVID-19 Serological TestingFemaleHEK293 CellsHumansImmunoglobulin AImmunoglobulin GSARS-CoV-2Antibodies, ViralImmunoglobulin AImmunoglobulin Gbinding antibodyCOVID-19functional antibodyhuman serumSARS-CoV-2serology

Identifiers

PMID34691016
PMCPMC8531527
OpenAlexW3206821891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.